Last update 14 Nov 2026

Trastuzumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-HER2/neu-MAb, Nanotrastuzumab, trastuzumab
+ [18]
Target
Action
antagonists
Mechanism
HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)
Originator Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (25 Sep 1998),
RegulationPriority Review (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
HER2 Positive Colorectal Cancer
Japan
28 Mar 2022
HER2 positive salivary gland cancer
Japan
25 Nov 2021
HER2-positive gastric cancer
Japan
10 Mar 2011
Stomach Cancer
United States
20 Oct 2010
Breast Cancer
Japan
04 Apr 2001
Early Stage Breast Carcinoma
European Union
28 Aug 2000
Early Stage Breast Carcinoma
Iceland
28 Aug 2000
Early Stage Breast Carcinoma
Liechtenstein
28 Aug 2000
Early Stage Breast Carcinoma
Norway
28 Aug 2000
HER2 Positive Breast Cancer
European Union
28 Aug 2000
HER2 Positive Breast Cancer
Iceland
28 Aug 2000
HER2 Positive Breast Cancer
Liechtenstein
28 Aug 2000
HER2 Positive Breast Cancer
Norway
28 Aug 2000
HER2 positive Gastroesophageal Junction Adenocarcinoma
European Union
28 Aug 2000
HER2 positive Gastroesophageal Junction Adenocarcinoma
Iceland
28 Aug 2000
HER2 positive Gastroesophageal Junction Adenocarcinoma
Liechtenstein
28 Aug 2000
HER2 positive Gastroesophageal Junction Adenocarcinoma
Norway
28 Aug 2000
Hormone receptor positive breast cancer
European Union
28 Aug 2000
Hormone receptor positive breast cancer
Iceland
28 Aug 2000
Hormone receptor positive breast cancer
Liechtenstein
28 Aug 2000
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Bladder CancerPhase 3
United Kingdom
-07 Mar 2023
Colorectal CancerPhase 3
United Kingdom
-07 Mar 2023
Gallbladder NeoplasmsPhase 3
United Kingdom
-07 Mar 2023
Hematologic NeoplasmsPhase 3
United Kingdom
-07 Mar 2023
Lung CancerPhase 3
United Kingdom
-07 Mar 2023
Ovarian CancerPhase 3
United Kingdom
-07 Mar 2023
Pancreatic CancerPhase 3
United Kingdom
-07 Mar 2023
Prostatic CancerPhase 3
United Kingdom
-07 Mar 2023
Salivary Gland NeoplasmsPhase 3
United Kingdom
-07 Mar 2023
Skin NeoplasmsPhase 3
United Kingdom
-07 Mar 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Metastatic Colorectal Carcinoma
HER2 overexpression/ERBB2 amplification
48
floijovhux(dtizzgcqex) = tnzajcabdc drykfbsfzx (gpnypkuubz, 0.38 - 0.64)
Positive
23 Oct 2026
Phase 2
HER2 Positive Breast Cancer
Neoadjuvant
HER2-positive
38
Neoadjuvant chemotherapy + Pyrotinib + trastuzumab
beicdesffv(dhxwljhvvd) = diarrhea (29, 76.3%) wbldhrkkoo (olzwcjocgn )
Positive
23 Oct 2026
Not Applicable
Gastrooesophageal junction cancer
HER2 | MSI-H/dMMR | PD-L1
345
qgjsjapykj(pqawvxrbmi) = fsfofqjejb jdtrnyftgr (dwyyjkupvs )
Positive
23 Oct 2026
Immune checkpoint inhibitors (ICIs)
qgjsjapykj(pqawvxrbmi) = rgoforrmmu jdtrnyftgr (dwyyjkupvs )
Phase 2
HER2 Positive Breast Cancer
Neoadjuvant
HER2-positive
15
zrzmkwtaei(zivjovzgwa) = yschueoujo byxxdtfytk (xnqdewljpl, 38.6 - 90.9)
Positive
23 Oct 2026
Phase 2
30
Radiation therapy + IT trastuzumab + pertuzumab
buyikotfzo(dqiyypttha) = ikwsykxpbc lljlpxsakb (dafxjglrhr )
Positive
23 Oct 2026
Phase 1
HER2 Positive Gastroesophageal Adenocarcinoma
First line
HER2-positive | PD-L1-positive
27
Nivolumab, trastuzumab, and chemotherapy
ilfybawlop(ihoynukjqv) = mmzqinwula yunuougkuy (fdoyohgjar )
Negative
23 Oct 2026
Nivolumab, trastuzumab, and chemotherapy
(EV-derived Cystatin C ≥ median)
ilfybawlop(ihoynukjqv) = kmssvcqkrm yunuougkuy (fdoyohgjar )
Not Applicable
697
Trastuzumab and taxane
luqquguvtd(epsoagcuur) = rpespctoca gmikvzytef (qrwgsvnjdj )
Positive
23 Oct 2026
luqquguvtd(epsoagcuur) = agauazfeiv gmikvzytef (qrwgsvnjdj )
Not Applicable
HER2 Positive Breast Cancer
Neoadjuvant
HER2-positive
160
rrdsnxcvsm(keueiamift) = yachkpozdg phfpuzxuth (ehhbjftext )
Positive
23 Oct 2026
Trastuzumab alone
wseprrsovn(xvofobuyln) = njhyftomif fgnycpbgvm (ewrhocedha )
Not Applicable
HER2 Positive Breast Cancer
Neoadjuvant
HER2-positive
74
Subcutaneous dual HER2 blockade
kiugyniejq(blepinczyv) = tfdfvasjmf loxkzjlgyu (eemwssswta )
Positive
23 Oct 2026
Intravenous dual HER2 blockade
kiugyniejq(blepinczyv) = gjnvwxqitx loxkzjlgyu (eemwssswta )
Phase 2
HER2 Positive Breast Cancer
Neoadjuvant
HER2-positive
72
rpbvygfmpr(yqeijccxrr) = vybtzcnozm iknsjcmftm (cafstlnmxr )
Positive
23 Oct 2026
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free